Aclaris Therapeutics Inc. (NASDAQ: ACRS) announced that additional data from its Phase 2a trial of ATI-2138 in atopic dermatitis will ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE